Acadia Pharmaceuticals is a biopharmaceutical company that discovers and commercializes treatments for underserved neurological and rare diseases. The company's revenue comes from two FDA-approved commercial products: NUPLAZID (pimavanserin), a selective serotonin inverse agonist for Parkinson's disease psychosis, and DAYBUE (trofinetide), a synthetic IGF-1 analog for Rett syndrome—each the first and only approved therapy in their respective indications. Beyond these core franchises, Acadia maintains a late-stage pipeline including remlifanserin for Alzheimer's and Lewy Body dementia psychosis and earlier-stage programs targeting conditions such as major depressive disorder, essential tremor, tardive dyskinesia, and other rare neurological disorders. The company distributes NUPLAZID through specialty pharmacies and distributors, manufactures products through established contract partners, and operates globally from headquarters in San Diego with significant operations in New Jersey and Switzerland.